文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

低中危前列腺癌超大分割质子放疗五年结局

Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-12

该研究分析284例低中危前列腺癌患者接受笔束扫描质子调强放疗(36.25 GyE/5次)的5年生化无病生存(bDFS)和晚期毒性,279例可分析。低危、有利中危、不利中危的5年bDFS分别为96.9%、91.7%、83.5%,晚期≥3级胃肠毒性0.36%、泌尿毒性0%,无前列腺癌相关死亡。

要点

  • 低、有利中危、不利中危的5年bDFS分别为96.9%、91.7%、83.5%。
  • 晚期≥3级胃肠毒性仅0.36%,泌尿≥3级毒性为0%。
  • 中位治疗时间9天,无前列腺癌相关死亡。

核心结论

  • 超大分割质子束放疗对前列腺癌有效,长期bDFS与其他分割方案相当,且严重晚期胃肠和泌尿毒性极少。

研究设计与样本

  • 2013年1月至2016年3月,284例前列腺癌患者接受笔束扫描质子调强放疗,方案为36.25 GyE分5次。
  • 5例失访被排除,最终前瞻性分析279例,中位随访56.5个月(范围3.4-87.5个月)。
  • 危险分组:低危121例(43.4%)、有利中危125例(44.8%)、不利中危33例(11.8%)。
  • 49例(17.6%)接受新辅助内分泌治疗,无患者接受辅助内分泌治疗。

主要发现

  • 中位治疗时间9天(范围7-18天)。
  • 5年bDFS:低危96.9%、有利中危91.7%、不利中危83.5%。
  • 晚期胃肠毒性:1级62例(22%)、2级20例(7.2%)、3级1例(0.36%)。
  • 晚期泌尿毒性:1级80例(28.7%)、2级14例(5%)、3级0例。
  • 17例(6.1%)出现PSA复发,11例检出淋巴结或骨复发,4例(1.4%)局部复发,9例(3.2%)死于非前列腺癌原因,无前列腺癌相关死亡。

关键数值与推荐

  • 5年bDFS低危96.9%、有利中危91.7%、不利中危83.5%。
  • 晚期胃肠毒性≥3级0.36%,泌尿≥3级0%。
  • PSA复发率6.1%,局部复发率1.4%。

临床怎么用

  • 对于低中危前列腺癌,超大分割质子放疗可获得与常规分割相当的5年生化控制。
  • 该方案严重晚期胃肠和泌尿毒性极低,支持其作为安全有效的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the 5-year biochemical disease-free survival (bDFS) and late toxicity profile in patients with prostate cancer treated with pencil beam scanning (PBS) proton radiation therapy. METHODS AND MATERIALS: Between January 2013 and March 2016, 284 patients with prostate cancer were treated using intensity modulated proton therapy (IMPT), with an ultrahypofractionated schedule (36.25 GyE in 5 fractions). Five patients were immediately lost from follow-up and thus were excluded from analysis. Data for 279 patients were prospectively collected and analyzed with a median follow-up time of 56.5 (range, 3.4-87.5) months. The mean age at time of treatment was 64.5 (40.1-85.7) years, and the median prostate-specific antigen (PSA) value was 6.35 μg/L (0.67-17.3 μg/L). A total of 121 (43.4%) patients had low-risk, 125 patients (44.8%) had favorable, and 33 (11.8%) unfavorable intermediate-risk cancer. In addition, 49 (17.6%) patients underwent neoadjuvant hormonal therapy, and no patients had adjuvant hormonal therapy. bDFS and late toxicity profiles were evaluated. RESULTS: The median treatment time was 9 days (range, 7-18 days). The 5-year bDFS was 96.9%, 91.7%, and 83.5% for the low-, favorable, and unfavorable intermediate-risk group, respectively. Late toxicity (Common Terminology Criteria for Adverse Events v.4) was as follows: gastrointestinal: grade 1, 62 patients (22%), grade 2, 20 patients (7.2%), and grade 3, 1 patient (0.36%); genitourinary: grade 1, 80 patients (28.7%), grade 2, 14 patients (5%), and grade 3, 0 patients. PSA relapse was observed in 17 patients (6.1%), and lymph node or bone recurrence was detected in 11 patients. Four (1.4%) local recurrences were detected. Nine patients (3.2%) died of causes unrelated to prostate cancer. No deaths related to prostate cancer were reported. CONCLUSION: Ultrahypofractionated proton beam radiation therapy for prostate cancer is effective with long-term bDFS comparable with other fractionation schedules and with minimal serious long-term GI and GU toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kubeš J, Haas A, Vondráček V, et al. Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes. Int J Radiat Oncol Biol Phys. 2021. PMID: 33587990. doi:10.1016/j.ijrobp.2021.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。